VolitionRx Secures €2M Non-Dilutive Funding from Belgian Agencies
Event summary
- VolitionRx received €2M in non-dilutive funding from Namur Invest and Wallonie Entreprendre S.A.
- Funding will support Nu.Q® product development, including regulatory transition and Lateral Flow product R&D.
- Total non-dilutive funding from all sources exceeds $25M.
- Funds will be disbursed in tranches over the next 12 months.
The big picture
VolitionRx's €2M non-dilutive funding underscores the strategic importance of regional government support in biotech development. The focus on regulatory transition and product expansion aligns with broader industry trends toward earlier disease detection and cost-effective diagnostics. The total $25M in non-dilutive funding highlights the company's ability to leverage public-private partnerships for growth.
What we're watching
- Regulatory Transition
- How the transition of Nu.Q® NETs from IVDD to IVDR will impact market access and regulatory compliance.
- Geographic Anchoring
- Whether VolitionRx can sustain its R&D and manufacturing presence in Wallonia with continued non-dilutive funding.
- Commercialization Pace
- The pace at which VolitionRx can expand commercialization efforts while maintaining clinical validation.
Related topics